SNCA and Parkinson disease: Current strategies to modify disease progression in PD have included agents targeting α-synuclein accumulation or cell-to-cell transmission, specific organelles such as mitochondria and lysosomes, associated proteins like β-glucocerebrosidase and leucine-rich repeat kinase 2, neuronal rescue pathways such as calcium channel blockers and iron reducers, and molecules involved in neuroinflammatory pathways4.